Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
Same as current

Summary

Conditions
Stress Urinary Incontinence
Type
Interventional
Phase
Not Applicable
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: A virtual prospective randomized controlled study to evaluate the efficacy of using the leva® PDHS to perform PFMT (leva arm) compared to standard care of a PFM exercise home program (Kegel arm) for the treatment of SUI or SMUI.Masking: Double (Investigator, Outcomes Assessor)Masking Description: Subjects will be randomized to either the leva® arm or Kegel arm on a 1 to 1 ratio using block randomization. Prior to initiation of the trial, a randomization sequence will be generated by the ObvioHealth system. Participants will be automatically allocated the next available slot in the sequence at the time of their randomization and assigned to the leva® or Kegel group accordinglyPrimary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 100 years
Gender
Only males

Description

This trial is entirely virtual. No office visits, specific locations, or physical examination will be required. Enrollment may occur from any location in the United States A virtual prospective randomized controlled study to evaluate the efficacy of using the leva® PDHS to perform PFMT (leva arm) co...

This trial is entirely virtual. No office visits, specific locations, or physical examination will be required. Enrollment may occur from any location in the United States A virtual prospective randomized controlled study to evaluate the efficacy of using the leva® PDHS to perform PFMT (leva arm) compared to standard care of a PFM exercise home program (Kegel arm) for the treatment of SUI or SMUI. Following completion of e-consent and screening, including an initial bladder diary and introductory phone call to review the study requirements, subjects are considered officially enrolled. A series of baseline assessments will be administered to all subjects to evaluate symptom severity, frequency and impact. Subjects will then be randomized to either the leva® arm or Kegel arm on a 1 to 1 ratio using block randomization. Prior to initiation of the trial, a randomization sequence will be generated by the ObvioHealth system. Participants will be automatically allocated the next available slot in the sequence at the time of their randomization and assigned to the leva® or Kegel group accordingly. Prior to beginning the program, subjects in the Kegel arm will receive printed instructions for PFMT with Kegel exercises. Subjects in the leva® arm will be shipped the leva® digital device, along with instructions for use and how to download the corresponding digital app. Day 1 of the study begins the day following receipt of materials. Study population: women with SUI or SMUI. The study requires no office visits. All participant data will be entered in the subject's smartphone using a custom designed mobile application. Participants will be able to interact with the app throughout the study period and will be presented with surveys and a voiding diary on a specified schedule during an 8-week treatment period. There will also be expected post-intervention follow up surveys at 6- and 12-months Using virtual recruiting, a total of up to 350 subjects will be enrolled in the trial. Subjects in both arms will have three scheduled phone calls with study staff during the first two weeks of treatment. Subjects can speak to the study staff at any time via an in-app chat function, the phone, or videoconference.

Tracking Information

NCT #
NCT04508153
Collaborators
  • OBVIO HEALTH USA, Inc.
  • University of Alabama at Birmingham
Investigators
Principal Investigator: Holly Richter, MD PhD University of Alabama at Birmingham Principal Investigator: Milena Weinstein, MD Massachusetts General Hospital Principal Investigator: Gena Dunnivan, MD University of New Mexico Principal Investigator: Noelani M Guaderrama, MD Southern California Permanentae